表皮生长因子受体(epidermal growth factor receptor, EGFR)突变是晚期非小细胞肺癌(non-small cell lung cancer, NSCLC)患者获益于酪氨酸激酶抑制剂(tyrosine kinase inhibitor, TKI)治疗的预测因子,本研究旨在探讨NSCLC原发灶与相应转移灶之间EGFR基因突变状况的不一致性。. Here, EGFR is linked to non-small cell lung carcinoma.